Sign Up! | Tags | Domains | Statistics | Options | Advanced Search
|
Sign Up! | Tags | Domains | Statistics | Options | Advanced Search |
xconomy.com » Xconomy Boston - 7 hours ago
Biotech, Devices, Patents Luke Timmerman wrote: Boston Scientific (NYSE: BSX) said today it scored a victory with a U.S. District Court in Texas. A jury had previously determined the Natick, MA-based medical device …
Also tagged: devices, patents, biotech, boston, medtronic, boston scientific, boston briefs, court of appeals
xconomy.com » Xconomy - 9 hours ago
Biotech, Life Sciences, ZymoGenetics Luke Timmerman wrote: ZymoGenetics, the Seattle biotech company that markets Recothrom for surgical bleeding, said today in a regulatory filing that it has sold a parcel of lake …
Also tagged: seattle, biotech, zymogenetics, seattle briefs, recothrom
computerzeitung.de » ComputerZeitung.de - 11 hours ago
In dem Projekt Lirec (LIving with Robots and intEractive Companions) werden – unter anderem auch mit dem Dinosaurier Pleo – soziale Beziehungen zwischen Menschen und Robotern erforscht. Erste Forschungsergebnisse …
Also tagged: forschung
xconomy.com » Xconomy Venture Capital Feed - 13 hours ago
Life Sciences, deals, Accelerator Ryan McBride wrote: The Massachusetts Technology Collaborative, the state’s development agency for the innovation economy, says it awarded a $50,000 planning grant to support the …
Also tagged: boston, deals, accelerator, boston briefs, massachusetts technology collaborative
 |
Impel NeuroPharma Develops Novel Delivery System to Get Drugs Into the Brainxconomy.com » Xconomy Seattle - 16 hours ago Biotech, Drugs, University of Washington Luke Timmerman wrote: Lots of drugs struggle to get into the brain. John Hoekman, the co-founder and chief scientific officer of a new University of Washington spinoff company … Also tagged: drugs, seattle, biotech, pain, university of washington, fentanyl, national blog main, seattle blog main, impel neuropharma, pharmaceutics, small business innovation research, center for innovation and entrepreneurship, michael hite, john hoekman, rodney ho |
xconomy.com » Xconomy Life Sciences Feed - 20 hours ago
Biotech, Multiple Sclerosis, Life Sciences Luke Timmerman wrote: Biogen Idec has made a lot of its money on Avonex and Tysabri, drugs that slow down the rate of flare-ups for people with multiple sclerosis. Now the …
Also tagged: drugs, biotech, boston, multiple sclerosis, cleveland clinic, wyeth, nature medicine, myelin, regenerative medicine, avonex, tysabri, lingo 1, boston blog main, national blog main, bruce trapp, genetics institute, sha mi, kenneth rhodes
xconomy.com » Xconomy - 20 hours ago
Biotech, cancer, Infectious Disease Luke Timmerman wrote: Spaltudaq has never really said a whole lot publicly about what it’s doing. So I was eager to get an update this week from CEO David Fanning about what’s …
Also tagged: cancer, seattle, biotech, hiv, autoimmune diseases, infectious disease, accelerator, canaan partners, ebola, national blog main, xconomy, seattle blog main, corixa, arch venture partners, healthcare ventures, mpm capital, alexandria real estate equities, institute for systems biology, johnny stine, spaltudaq, amgen ventures, david fanning
xconomy.com » Xconomy Seattle - 20 hours ago
Biotech, Devices, Ultrasound Luke Timmerman wrote: Sonosite, the Bothell, WA-based maker of portable ultrasound machines, said today that Thomas Dugan, its senior vice president of global marketing and U.S. sales, is …
Also tagged: devices, seattle, biotech, ultrasound, sonosite, seattle briefs, smith and 38 nephew, thomas dugan
xconomy.com » Xconomy Life Sciences Feed - Aug 28, 2008
Biotech, Devices, Ultrasound Luke Timmerman wrote: Sonosite, the Bothell, WA-based maker of portable ultrasound machines, said today that Thomas Dugan, its senior vice president of global marketing and U.S. sales, is …
Also tagged: devices, seattle, biotech, ultrasound, sonosite, seattle briefs, smith and 38 nephew, thomas dugan
 |
Spaltudaq Harnessing Mother Nature’s Wisdom to Make Better Drugs For Infectionsxconomy.com » Xconomy Seattle - Aug 28, 2008 Biotech, cancer, Infectious Disease Luke Timmerman wrote: Spaltudaq has never really said a whole lot publicly about what it’s doing. So I was eager to get an update this week from CEO David Fanning about what’s … Also tagged: cancer, seattle, biotech, hiv, autoimmune diseases, infectious disease, accelerator, canaan partners, ebola, national blog main, xconomy, seattle blog main, corixa, arch venture partners, healthcare ventures, mpm capital, alexandria real estate equities, institute for systems biology, johnny stine, spaltudaq, amgen ventures, david fanning |